Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms. 
  • Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates to treat various life-threatening and debilitating diseases.
  • UCLA will work to propose potential antibody drug candidates. The collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements for selected candidates.
  • Price Action: XNCR closed 0.3% higher at $48.5 on Wednesday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareContractsGeneral